Limb ischemia in patients with COVID-19
Isquemia de membros em pacientes com COVID-19
Julio Cesar Peclat de Oliveira; Walter Jr. Boim Araujo; Sergio Quilici Belczak; Fabiano Luiz Erzinger; Lucas Maia Peclat de Oliveira; Marcos Arêas Marques; Lucas Mansano Sarquis; Bianca Gutfilen
Abstract
Keywords
Resumo
Resumo: Esta revisão narrativa abrange os eventos tromboembólicos com risco de vida associados a infecção por SARS-CoV-2/COVID-19. Aborda as mudanças físicas que causam danos vasculares e arteriais aos membros, o manejo laboratorial da coagulação e o manejo da anticoagulação. A relação de COVID-19 com trombose venosa profunda e trombose arterial também é enfatizada. Os principais eventos tromboembólicos descritos na literatura são ilustrados a partir de nossa experiência com pacientes COVID-19.
Palavras-chave
References
1 García Herrera AL, Moliner Cartaya M. Caracterización clínica de la trombosis venosa profunda em enfermos con VIH/SIDA. Rev Méd Electrón. 2010;32(3):1-8.
2 Ramacciotti E, Agati LB, Aguiar VCR, et al. Zika and Chikungunya virus and risk for venous thromboembolism. Clin Appl Thromb Hemost. 2019;25:1076029618821184.
3 Marques MA, Adami de Sá FP, Lupi O, Brasil P, von Ristow A. Deep venous thrombosis and chikungunya virus. J Vasc Bras. 2017;16(1):60-2.
4 Goeijenbier M, van Wissen M, van de Weg C, et al. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012;84(10):1680-96.
5 Avnon LS, Munteanu D, Smoliakov A, Jotkowitz A, Barski L. Thromboembolic events in patients with severe pandemic influenza A/H1N1. Eur J Intern Med. 2015;26(8):596-8.
6 Wang C-C, Chang C-T, Lin C-L, Lin I-C, Kao C-H. Hepatitis C virus infection associated with an increased risk of deep vein thrombo- sis: a population-based cohort study. Medicine. 2015;94(38):e1585.
7 Mei H, Hu Y. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19. Zhonghua Xue Ye Xue Za Zhi. 2020;41(3):185-91.Article in Chinese. PMid:32133825.
8 Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-8.
9 Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34-45.
10 Delabranche X, Helms J, Meziani F. Immunohaemostasis: a new view on haemostasis during sepsis. Ann Intensive Care. 2017;7(1):117.
11 Zhang T, Sun LX, Feng RE. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(6):496-502. Article in Chinese. PMid:32241072.
12 Chinese Association of Rehabilitation Medicine. Respiratory Rehabilitation Committee of Chinese Association of Rehabilitation Medicine. Cardiopulmonary Rehabilitation Group of Chinese Society of Physical Medicine and Rehabilitation. Recommendations for respiratory rehabilitation of coronavirus disease 2019 in adult. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(4):308-14. Article in Chinese. PMid:32294814.
13 Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2018;16(2):231-41.
14 Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2019;17(2):283-94.
15 Iba T, Levy JH, Wada H, Thachil J, Warkentin TE, Levi M. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost. 2019;17(2):415-9.
16 Iba T, Arakawa M, Ohchi Y, et al. Prediction of early death in patients with sepsis- associated coagulation disorder treated with antithrombin supplementation. Clin Appl Thromb Hemost. 2018;24(9, Suppl):145-9S.
17 Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4(1):90-7.
18 Yamakawa K, Levy JH, Iba T. Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Crit Care. 2019;23(1):302.
19 Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
20 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
21 Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40.
22 Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43.
23 Zhang T, Sun LX, Feng RE. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(6):496-502. Article in Chinese. PMid:32241072.
24 Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7.
25 Cronin M, Dengler N, Krauss ES, et al. Completion of the updated Caprini risk assessment model (2013 Version). Clin Appl Thromb Hemost. 2019;25.
26 Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18(5):1020-2.
27 Khan IH, Savarimuthu S, Leung MST, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg. 2020;72(3):799-804.
28 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-9.
29 Iba T, Levy JH, Levi M, Connors JM. Thachil. Coagulopathy of coronavirus disease 2019. Crit Care Med. In press.
30 Masana M, Martinez LI, Gil M, Bueno G, Llagostera S. Thoracic Aortic Mural Thrombus, Right Ventricular Clot and Pulmonary Embolism in a Patient With COVID-19 Pneumonia. Vasc Endovascular Surg. 2021;55(3):273-6.
31 Mei H, Hu Y. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19. Zhonghua Xue Ye Xue Za Zhi. 2020;41(3):185-91. Article in Chinese. PMid:32133825.
32 Zhang L, Feng X, Zhang D, et al. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors, and outcome. Circulation. 2020;142(2):114-280.
33 Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8.
34 Perini P, Nabulsi B, Massoni CB, Azzarone M, Freyrie A. Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19. Lancet. 2020;395(10236):1546.
35 Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID- 19. J Thromb Haemost. 2020;18(5):1023-6.
36 Cantador E, Núñez A, Sobrino P, et al. Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients. J Thromb Thrombolysis. 2020;50(3):543-7.
37 Veerasuri S, Kulkarni SR, Wilson WR, Paravastu SCV. Bilateral acute lower limb ischemia secondary to COVID-19. Vasc Endovascular Surg. 2021;55(2):196-9.
38 Fan BE, Chia YW, Sum CLL, et al. Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia. J Thromb Thrombolysis. 2020;50(2):292-7.